Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
COVID-19
Fingolimod
Multiple sclerosis
Ocrelizumab
SARS-CoV-2 vaccination
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
31
05
2021
accepted:
11
06
2021
revised:
10
06
2021
pubmed:
1
7
2021
medline:
11
1
2022
entrez:
30
6
2021
Statut:
ppublish
Résumé
Recent observations suggest a lack of humoral response after SARS-CoV-2 vaccination in multiple sclerosis (MS) patients treated with fingolimod or ocrelizumab OBJECTIVES: To assess serological response to SARS-CoV-2 vaccination in MS patients receiving these disease-modifying treatments (DMTs) in a real-life setting. Retrospective clinical data collection from MS patients followed at San Raffaele Hospital MS Centre (Milan, Italy). All patients treated with fingolimod or ocrelizumab who had received a complete anti-COVID-19 vaccination course, with no clinical history suggestive of previous SARS-CoV-2 infection and with an available post-vaccination serological assay obtained at least 14 days after vaccination completion were considered for the study. We collected data from 32 MS patients, 16 treated with fingolimod and 16 receiving ocrelizumab. Among the fingolimod group 10 patients (62.5%) had a positive serological response after vaccination and among ocrelizumab-treated patients a positive serological test was found in six cases (37.5%). No relation between serological response and clinical features (i.e., treatment duration, time between vaccination and last treatment dose, and white blood cells count) was identified. Our initial real-life experience suggests a variable antibody production in MS patients receiving these DMTs. At present, there are no sufficient data to do not recommend anti-SARS-CoV-2 vaccine in these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Recent observations suggest a lack of humoral response after SARS-CoV-2 vaccination in multiple sclerosis (MS) patients treated with fingolimod or ocrelizumab OBJECTIVES: To assess serological response to SARS-CoV-2 vaccination in MS patients receiving these disease-modifying treatments (DMTs) in a real-life setting.
METHODS
METHODS
Retrospective clinical data collection from MS patients followed at San Raffaele Hospital MS Centre (Milan, Italy). All patients treated with fingolimod or ocrelizumab who had received a complete anti-COVID-19 vaccination course, with no clinical history suggestive of previous SARS-CoV-2 infection and with an available post-vaccination serological assay obtained at least 14 days after vaccination completion were considered for the study.
RESULTS
RESULTS
We collected data from 32 MS patients, 16 treated with fingolimod and 16 receiving ocrelizumab. Among the fingolimod group 10 patients (62.5%) had a positive serological response after vaccination and among ocrelizumab-treated patients a positive serological test was found in six cases (37.5%). No relation between serological response and clinical features (i.e., treatment duration, time between vaccination and last treatment dose, and white blood cells count) was identified.
CONCLUSIONS
CONCLUSIONS
Our initial real-life experience suggests a variable antibody production in MS patients receiving these DMTs. At present, there are no sufficient data to do not recommend anti-SARS-CoV-2 vaccine in these patients.
Identifiants
pubmed: 34189719
doi: 10.1007/s00415-021-10663-x
pii: 10.1007/s00415-021-10663-x
pmc: PMC8241206
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antibodies, Viral
0
COVID-19 Vaccines
0
ocrelizumab
A10SJL62JY
Fingolimod Hydrochloride
G926EC510T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
39-43Informations de copyright
© 2021. The Author(s).
Références
Ellul M, Benjamin L, Singh B, Lant S, Michael BD, Easton A et al (2020) Neurological associations of COVID-19. Lancet Neurol 19(9):767–783. https://doi.org/10.1016/S1474-4422(20)30221-0
doi: 10.1016/S1474-4422(20)30221-0
pubmed: 32622375
pmcid: 7332267
Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C et al (2020) Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 77(9):1079–1088. https://doi.org/10.1001/jamaneurol.2020.2581
doi: 10.1001/jamaneurol.2020.2581
pubmed: 32589189
Chaudhry F, Jageka C, Levy PD, Cerghet M, Lisak RP (2021) Review of the COVID-19 risk in multiple sclerosis. J Cell Immunol 3(2):68–77. https://doi.org/10.33696/immunology.3.080
doi: 10.33696/immunology.3.080
pubmed: 33959727
pmcid: 8098748
Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L et al (2021) Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 89(4):780–789. https://doi.org/10.1002/ana.26028
doi: 10.1002/ana.26028
pubmed: 33480077
pmcid: 8013440
Moiola L, Barcella V, Benatti S, Marco Capobianco M, Capra R, Cinque P et al (2021) The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a Delphi consensus statement. Mult Scler 27(3):331–346. https://doi.org/10.1177/1352458520952311
doi: 10.1177/1352458520952311
pubmed: 32940121
Kelly H, Sokola B, Abboud H (2021) Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. J Neuroimmunol 4(356):577599. https://doi.org/10.1016/j.jneuroim.2021.577599
doi: 10.1016/j.jneuroim.2021.577599
Achiron A, Dolev M, Menascu S, Zohar DN, Dreyer-Alster S, Miron S et al (2021) COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler 27(6):864–870. https://doi.org/10.1177/13524585211003476
doi: 10.1177/13524585211003476
pubmed: 33856242
pmcid: 8114441
Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P et al (2021) Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord 14:1–8. https://doi.org/10.1177/17562864211012835
doi: 10.1177/17562864211012835
Roy S, Boschert U (2021) Analysis of influenza and varicella zoster virus vaccine antibody titers in patients with relapsing multiple sclerosis treated with cladribine tablets. Presented at ACTRIMS Forum 2021 as Poster Communication (P071)
Bonelli MM, Mrak D, Perkmann T, Haslacher H, Aletaha D (2021) SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2021-220408
doi: 10.1136/annrheumdis-2021-220408
pubmed: 34380700